Back to Search Start Over

The Double-Blind Variable Placebo Lead-in Period: Results From Two Antidepressant Clinical Trials

Authors :
William Z. Potter
Douglas E. Faries
Gary D. Tollefson
John H. Heiligenstein
Source :
Journal of Clinical Psychopharmacology. 21:561-568
Publication Year :
2001
Publisher :
Ovid Technologies (Wolters Kluwer Health), 2001.

Abstract

The 1-week single-blind placebo lead-in has long been a standard in double-blind psychopharmacology clinical trials. Although a lead-in period is often necessary (e.g., to receive laboratory results before randomization), some authors have demonstrated that the standard single-blind placebo lead-in's performance was similar to having a lead-in in which placebo was not administered. The single-blind placebo lead-in did not decrease postrandomization placebo response, nor did it increase drug-placebo differences. To eliminate a higher percentage of placebo responders before randomization and to reduce potential biases in baseline ratings, the authors designed and implemented two depression studies with a double-blind variable placebo lead-in period. In these designs, both the patients and personnel at the investigative sites were blinded to the length of the placebo lead-in period and the start of the active treatment period. Approximately 28% of the patients in the double-blind placebo lead-in studies met criteria to be placebo lead-in responders, as compared with fewer than 10% from two single-blind placebo lead-in studies conducted in a similar time frame. Although all patients continued in the study (including placebo lead-in responders), the primary efficacy analysis prospectively excluded double-blind placebo lead-in responders. Analysis of postrandomization changes revealed that double-blind placebo lead-in responders, even when continuing to receive placebo treatment, maintained their response. At the study endpoint, these placebo lead-in responders had significantly lower severity scores than their counterparts who were not lead-in responders. The prospective removal of lead-in responders thus resulted in an increase in mean endpoint placebo group severity scores. This resulted in an increased drug-placebo treatment difference in one of the two studies but had no effect on the treatment difference in the other study.

Details

ISSN :
02710749
Volume :
21
Database :
OpenAIRE
Journal :
Journal of Clinical Psychopharmacology
Accession number :
edsair.doi.dedup.....08b50e3cb712b464a6a290ec0974b8b5
Full Text :
https://doi.org/10.1097/00004714-200112000-00004